- Home
- ELTX vs SRBK Comparison
ELTX vs SRBK Comparison
Compare ELTX & SRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELTX
- SRBK
- Stock Information
- Founded
- ELTX 2011
- SRBK 1887
- Country
- ELTX United States
- SRBK United States
- Employees
- ELTX N/A
- SRBK N/A
- Industry
- ELTX Biotechnology: Pharmaceutical Preparations
- SRBK
- Sector
- ELTX Health Care
- SRBK
- Exchange
- ELTX Nasdaq
- SRBK Nasdaq
- Market Cap
- ELTX 49.7M
- SRBK 96.1M
- IPO Year
- ELTX 2021
- SRBK N/A
- Fundamental
- Price
- ELTX $4.16
- SRBK $10.81
- Analyst Decision
- ELTX Buy
- SRBK
- Analyst Count
- ELTX 2
- SRBK 0
- Target Price
- ELTX $10.00
- SRBK N/A
- AVG Volume (30 Days)
- ELTX 16.1K
- SRBK 20.6K
- Earning Date
- ELTX 11-07-2024
- SRBK 01-01-0001
- Dividend Yield
- ELTX N/A
- SRBK N/A
- EPS Growth
- ELTX N/A
- SRBK N/A
- EPS
- ELTX N/A
- SRBK N/A
- Revenue
- ELTX N/A
- SRBK $22,814,000.00
- Revenue This Year
- ELTX N/A
- SRBK N/A
- Revenue Next Year
- ELTX N/A
- SRBK N/A
- P/E Ratio
- ELTX N/A
- SRBK N/A
- Revenue Growth
- ELTX N/A
- SRBK 52.54
- 52 Week Low
- ELTX $2.96
- SRBK $8.01
- 52 Week High
- ELTX $11.45
- SRBK $11.24
- Technical
- Relative Strength Index (RSI)
- ELTX 40.82
- SRBK 51.76
- Support Level
- ELTX $4.05
- SRBK $10.97
- Resistance Level
- ELTX $4.89
- SRBK $11.09
- Average True Range (ATR)
- ELTX 0.28
- SRBK 0.06
- MACD
- ELTX -0.06
- SRBK -0.05
- Stochastic Oscillator
- ELTX 27.37
- SRBK 5.50
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.
About SRBK SR Bancorp Inc. Common stock
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.